278650 — HLB BioStep Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩338bn
- KR₩321bn
- KR₩86bn
2018 December 31st | 2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Interim Report |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3,839 | 16,202 | 14,910 | 10,393 | 97,045 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,789 | 6,946 | 8,829 | 10,153 | 10,148 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 16,254 | 29,228 | 28,579 | 31,178 | 112,424 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 18,382 | 23,146 | 26,226 | 39,867 | 39,626 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 43,741 | 61,531 | 74,215 | 94,626 | 172,187 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 10,217 | 12,090 | 15,379 | 16,582 | 12,775 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 23,072 | 19,667 | 20,572 | 30,038 | 101,909 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 20,669 | 41,864 | 53,643 | 64,587 | 70,278 |
Total Liabilities & Shareholders' Equity | 43,741 | 61,531 | 74,215 | 94,626 | 172,187 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |